Small Pharma Inc. (OTCQB:DMTTF), a biotech company that develops short-acting psychedelic-assisted therapies for depression, received approval from the U.K. Medicines and Healthcare products Regulatory Authority (MHRA) and the Research Ethics Committee to begin a Phase 1 clinical study of its deuterated form of DMT, SPL028.
“Progressing our second candidate towards the clinic marks a significant step for Small Pharma. Our focus continues to be in evaluating short-acting psychedelic therapies due to their potential as scalable treatments, which we see as critical given the magnitude of the mental health crisis,” CEO George Tziras stated.
